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Dominant-negative (DN) mutations in the nuclear
hormone receptor peroxisome proliferator-activated
receptor-g (PPARg) cause hypertension by an
unknown mechanism. Hypertension and vascular
dysfunction are recapitulated by expression of DN
PPARg specifically in vascular smooth muscle of
transgenic mice. DN PPARg increases RhoA and
Rho-kinase activity, and inhibition of Rho-kinase
restores normal reactivity and reduces arterial pres-
sure. RhoBTB1, a component of the Cullin-3 RING
E3 ubiquitin ligase complex, is a PPARg target
gene. Decreased RhoBTB1, Cullin-3, and neddylated
Cullin-3 correlated with increased levels of the
Cullin-3 substrate RhoA. Knockdown of Cullin-3 or
inhibition of cullin-RING ligase activity in aortic
smooth muscle cells increased RhoA. Cullin-RING
ligase inhibition enhanced agonist-mediated con-
traction in aortic rings from normal mice by a Rho-
kinase-dependent mechanism, and it increased
arterial pressure in vivo. We conclude that Cullin-3
regulates vascular function and arterial pressure,
thus providing a mechanistic link between mutations
in Cullin-3 and hypertension in humans.
INTRODUCTION
PPARg is activated by thiazolidinediones (TZDs), a class of
insulin-sensitizing drugs. TZD treatment attenuates the develop-
ment of hypertension and inhibits atherosclerosis in type II dia-
betes patients (Halabi and Sigmund, 2005). Known adverse
effects of TZD treatment include weight gain and systemic
edema. Clinical studies report an increased risk of myocardial
infarction and heart failure in patients taking the TZD rosiglita-
zone (Graham et al., 2010)—and more recently concerns of
increased risk of bladder cancer have surfaced with pioglitazone
(Lewis et al., 2011). TZDs increase water and salt retention by the
kidneys, yet their use consistently lowers blood pressure,
suggesting that the antihypertensive effects of tissue-specific
PPARg activation in nonrenal tissues are potent (Ketsawatsomk-
ron et al., 2010). While PPARg is well characterized as a master462 Cell Metabolism 16, 462–472, October 3, 2012 ª2012 Elsevier Inregulator of adipogenesis, the direct actions of PPARgwithin the
vasculature remain unclear. Given the concerns over TZD use,
understanding the fundamental mechanisms of PPARg action
in specific tissues is essential in order to identify therapeutic
pathways that promote the beneficial actions of PPARg while
minimizing detrimental actions. A new class of non-TZD ligands
that prevent Cyclin-dependent kinase 5 (Cdk5)-dependent
inhibition of PPARg and lack agonist activity may provide
a similar level of glycemic control as TZD but without adverse
effects on weight gain and fluid retention (Choi et al., 2011).
Individuals carrying mutations (i.e., P467L, V290M) and
knockin mice with an equivalent mutation (P465L) in PPARg
develop early-onset hypertension (Barroso et al., 1999; Tsai
et al., 2004). Mutation of the ligand-binding domain of PPARg
prevents ligand activation but retains its ability to bind DNA
and complex with corepressors. Thus, these mutations confer
dominant-negative (DN) activity, which alters PPARg-mediated
transcription (Li and Leff, 2007). We demonstrated that smooth
muscle cell-targeted expression of DN human PPARg in trans-
genic mice (termed S-P467L) caused elevated blood pressure
and vascular dysfunction independent of changes in systemic
metabolism (Halabi et al., 2008). This and other studies employ-
ing vascular-specific knockout of PPARg are consistent with the
hypothesis that PPARg activation exerts its antihypertensive
and vascular protective effects through actions in vascular endo-
thelium and smooth muscle. Therefore, the aim of the current
study is to elucidate the molecular mechanisms that underlie
augmented contraction and impaired relaxation induced by
expression of DN PPARg in smooth muscle.
RESULTS
DN PPARg-Induced Aortic Dysfunction Is
Smooth-Muscle Specific
Smooth-muscle-specific expression of DN PPARg in S-P467L
mice caused severely impaired relaxation to Ach and SNP (Fig-
ure 1A). Preincubation of aortic rings with L-NAME or removal
of the endothelium completely abrogated Ach-induced relaxa-
tion in both S-P467L and NT but had no effect on SNP-induced
relaxation (Figures 1A and S1A). The impairment in vasodilation
is not due to increased superoxide because preincubation with
Tempol, a scavenger of superoxide, did not alter the responses
to either Ach or SNP (Figure S1B). The level of total and phospho-
Ser1177 eNOS protein was similar in aortic tissue from NT and
S-P467L mice (Figure S1C). ET-1 and 5-HT caused enhancedc.
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Figure 1. Interference with PPARg Causes Increased Rho-Kinase Activity
(A and B) Isometric tension was measured on aortic rings from S-P467L (black) and NT littermates (gray). Dose-dependent relaxation (following precontraction
with prostaglandin F2a [PGF2a]) in response to acetylcholine (Ach) and sodium nitroprusside (SNP) (A), contraction in response to endothelin 1 (ET-1) (B) was
recorded in the absence or presence of NOS inhibitor (30 min preincubation; L-NAME, 100 mmol/L) (n = 6-12).
(C) ELISA of phospho-Thr696 MYPT1 subunit of MLCP in the absence or presence of Rho-kinase inhibitor (Y-27632) using aortic tissue fromNT and S-P467Lmice
(n = 4-9) and quantification of Y-27632-sensitive Rho-kinase activity.
(D and E) Effect of Rho-kinase inhibition (30 min preincubation; Y-27632, 1 mmol/L) on contraction or relaxation of aortic rings from S-P467L and NT mice in
response to ET-1 (D) or Ach and SNP (E) (n = 9–12).
(F) Direct blood pressure measurements were recorded in response to acute intravenous injection of the Rho-kinase inhibitor Y-27632 in anesthetized NT and
S-P467L mice (n = 6). See also Figures S1 and S2. *p < 0.05 S-P467L versus NT. # p < 0.05 treated versus nontreated. Error bars represent SEM.
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PPARg Regulates Vascular Function via Cullin-3contraction of S-P467L aorta, which was augmented by either
NOS inhibition or removal of the endothelium (Figures 1B, S1D,
and S1E). As above, pretreatment with Tempol had no effect
on agonist-induced contraction (Figure S1F). These data sug-
gest that NO production and bioavailability is unaltered and
that aortic dysfunction in S-P467L mice is due to some other
mechanism.
DN PPARg Increases Rho-Kinase Activity
We tested the hypothesis that the RhoA/Rho-kinase pathway is
a downstream target of PPARg and that enhanced activation of
Rho-kinase limits the effectiveness of NO/PKG signaling in S-
P467L (Chitaley and Webb, 2002). Basal Rho-kinase activity,
measured by Thr696 phosphorylation of the myosin light chain
phosphatase subunit MYPT1, was significantly increased in
lysates from S-P467L aorta (Figure 1C). The increase in Rho-
kinase activity was inhibited by Y-27632, a specific inhibitor of
both Rho-kinase isoforms ROCK1 and ROCK2 (Figure 1C).
Consistent with this, preincubation of aortic rings with Y-27632
blunted the hypercontractile responses from S-P467L aorta
(Figures 1D and S2A), thus demonstrating that the enhanced
contraction is Rho-kinase dependent. Importantly, preincuba-Celltion with Y-27632 fully restored NO-mediated dilator responses
in S-P467L aorta (Figure 1E). The improvement in Ach-induced
relaxation after Rho-kinase blockade in S-P467L aorta was
abrogated by NOS inhibition or endothelium removal indicating
it is endothelium dependent (Figure S2B). This suggests that
increased activity of the Rho-kinase pathway in smooth muscle
is responsible for the DNPPARg-induced defect in NO-mediated
relaxation. Likewise, intravenous injection of Y-27632 decreased
mean arterial pressure by 30 ± 3 mmHg in S-P467L mice
compared with 16 ± 1 mmHg (p < 0.05) in NT mice (Figure 1F),
strongly suggesting the increase in arterial pressure caused by
DN PPARg is Rho-kinase dependent.
Because Rho-kinase enhances the sensitivity of the contrac-
tile apparatus to Ca2+, we tested if contraction to CaCl2 was
enhanced in ionomycin-permeabilized aortic rings. Aorta
from S-P467L mice displayed increased contraction at lower
concentrations of CaCl2 compared to NT mice (S-P467L
EC50 = 4.3mmol/L versus NT EC50 = 22.1mmol/L; p < 0.05) while
maximum contraction was not different (Figure S2C). Similar to
receptor-mediated agonists, Bay K8644 augmented contraction
in S-P467L aorta that was both NO- and Rho-kinase dependent
(Figure S2D). On the contrary, the PKC activator phorbolMetabolism 16, 462–472, October 3, 2012 ª2012 Elsevier Inc. 463
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Figure 2. Increased RhoA Protein Expression and Activity
(A) Protein levels of ROCK1 and ROCK2 (n = 4–5) or RhoA (n = 8) in entire aorta of NT and S-P467L mice determined by western blot.
(B) Expression of ROCK1, ROCK2, and RhoA mRNA in aortic tissue determined by qPCR (n = 10–11).
(C) Total RhoA protein levels in medial aorta (dissected free of endothelium and adventitia) (n = 8) or 1 aortic smooth muscle cells (SMC) (n = 6) determined by
western blot and quantification.
(D) Western blot of RhoA-GTP pull-down using nontreated 1 aortic SMC from NT and S-P467L mice (n = 4), and aortic rings equilibrated to 0.5 g tension plus or
minus agonist-stimulation by 5-HT (1 mmol/L, 5min) (n = 4), and quantification. ‘‘NS’’ indicates nonspecific band. See also Figure S3. *p < 0.05 S-P467L versus NT.
# p < 0.05 treated versus non-treated. Error bars represent SEM.
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PPARg Regulates Vascular Function via Cullin-312,13-dibutyrate (PdBu) produced contraction that was similar
between NT and S-P467L aorta and was not sensitive to
L-NAME nor Y-27632 pre-incubation (Figure S2E).
DN PPARg Increases RhoA Protein and Activity
Themechanism for increased Rho-kinase activity was not due to
a change in the protein levels of ROCK1 and ROCK2 (Figure 2A).
On the contrary, the protein level of RhoA GTPase, which lies
upstream and is a primary regulator of Rho-kinase, was
increased in entire aorta from S-P467L mice under baseline
conditions (Figure 2A). Despite this, the level of RhoA mRNA
was unchanged in S-P467L aorta (Figure 2B). ROCK1 and
ROCK2 mRNA levels were also unchanged (Figure 2B). The
increase in RhoA is specific to the smooth muscle since RhoA
protein was increased in medial aortic tissue (e.g., dissected
free of endothelium and adventitia) and in primary aortic smooth
muscle cells from S-P467L mice (Figure 2C). Increased total
RhoA protein correlated with a greater basal level of active
GTP-bound RhoA in primary aortic smooth muscle cells from
S-P467L. Next, we determined the levels of GTP-bound RhoGT-
Pases in basal or agonist-stimulated aortic rings equilibrated to
resting tension (0.5 g). While the basal level of RhoA-GTP was
not different between S-P467L and NT aortic rings at resting
tension, 5-HT stimulation significantly increased RhoA-GTP
to a greater extent in S-P467L aorta (Figure 2D). 5-HT produced
the maximal difference in contraction between genotypes464 Cell Metabolism 16, 462–472, October 3, 2012 ª2012 Elsevier In(Figures S1D–S1F), and it induces GTP-bound RhoA (Sakurada
et al., 2001). The level of GTP-bound Rac1 was unaffected by
5-HT stimulation and was not different between genotypes (Fig-
ure S3A). GTP-bound Cdc42 was not detected in the basal or
stimulated state, but could be detected in control lysates incu-
bated with GTPgS (Figure S3B). Like RhoA, Rac1 and Cdc42
mRNA were unchanged in S-P467L aorta (Figure S3C). These
data suggest that interference with PPARg in smooth muscle
leads to enhanced Rho-kinase activity via increased expression
and activity of its upstream regulator RhoA.
PPARg Regulates RhoBTB1 Expression
To gather insights into themolecular mechanism for the increase
in RhoA/Rho-kinase activity, we performed gene-expression
profiling on aorta from NT and S-P467L mice by employing
both oligonucleotide and exon tiling arrays. Numerous PPARg
target genes related to lipid metabolism were downregulated
by DN PPARg in the aorta of S-P467L mice, consistent with
PPARg’s role as a major regulator of adipogenesis. However,
we focused on RhoBTB1, which was markedly decreased (Fig-
ure 3A), because it has previously been implicated to bind to
Cullin-3 (Berthold et al., 2008), a cullin-RING E3 ubiquitin ligase
complex scaffold protein that regulates the turnover of RhoA
(Chen et al., 2009). RhoBTB1 mRNA and protein was decreased
by approximately 72% and 34% as confirmed by real-time
quantitative RT-PCR (Figure 3A) and western blot (Figure 3B),c.
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Figure 3. Identification of the Cullin-3-Interacting Protein RhoBTB1 as a PPARg Target Gene
(A) RelativemRNA expression of RhoBTB1 in aortic tissue fromS-P467Lmice relative to NT littermates in two independentmicroarray experiments using different
array platforms and validation byQ-PCR (n = 10–11). Oligo array refers to the Affymetrixmouse genome 2.0 array (probe set 1429656_at, n = 2 for NT, and n = 3 for
S-P467L), and exon array refers to the Affymetrix mouse exon 1.0 ST array (probe set 6768601, n = 5 for NT, and n = 7 for S-P467L).
(B) Western blot for RhoBTB1protein expression in aorta from S-P467L and littermate NT mice (n = 8) or from S-WT and littermate NT mice (n = 4) and quan-
tification. ‘‘NS’’ indicates nonspecific band.
(C) Validation of PPARg and RXR binding at FABP4 and RhoBTB1 PPREs by ChIP from duplicate experiments. Data are displayed as the fold enrichment relative
to the IgG signal at the region of interest (*p < 0.05 Pparg or RXR versus IgG). NG represents a nonspecific region of the genome that does not contain any known
PPRE sequences.
(D) Immunoprecipitation (IP) experiments using HEK293T cells transfected with plasmids expressingMyc-RhoBTB1, Flag-Cullin-3, or both. The antisera used for
each IP is indicated. Lysates indicate samples not subjected to IP as controls for antisera specificity. Cells were treated with either MG132 (5 mmol/L) or vehicle
(DMSO). The left blots are representative of n = 4, and the right blot was representative of duplicate experiments. See also Figure S4. *p < 0.05 S-P467L or S-WT
versus NT. Error bars represent SEM.
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PPARg Regulates Vascular Function via Cullin-3respectively. Evidence suggesting RhoBTB1 is a PPARg target
gene was 3-fold. First, expression of RhoBTB1 protein was
increased in aorta from transgenic mice overexpressing wild-
type PPARg in smooth muscle (S-WT mice, Figure 3B). Second,
PPARg and retinoid X receptor (RXR) binding sites were de-
tected at the RhoBTB1 locus by genome-wide chromatin immu-
noprecipitation (ChIP, Figure S4A). Third, we validated PPARg
binding at the RhoBTB1 locus using ChIP in differentiated
3T3-L1 cells (Figure 3C). Cullin-3 is known to interact with
many BTB domain-containing proteins, including RhoBTBs,
which may act as substrate adaptors and/or direct substrates
of Cullin-3-dependent ubiquitylation (Berthold et al., 2008).
Reciprocal IP, employing Flag-tagged Cullin-3 and Myc-tagged
RhoBTB1 coexpressed in HEK293T cells, revealed direct inter-
action between RhoBTB1 and Cullin-3 that was not affected by
proteasome inhibition (Figure 3D).
DN PPARg Impairs Cullin-3
The increase in total RhoA protein, but not mRNA, coupled with
decreased RhoBTB1, suggested the hypothesis that DN PPARg
in smooth muscle interferes with Cullin-3-mediated posttransla-
tional regulation of RhoA. Cullin-3 protein and the ratio of neddy-
lated Cullin-3 to unneddylated Cullin-3 was decreased in aorta
from S-P467L mice (Figures 4A and 4B). The covalent attach-
ment of Nedd8, called neddylation, is required for cullin-depen-Celldent ubiquitin ligase activity (Wu et al., 2005). Total Nedd8
conjugates were detected only at the molecular weight corre-
sponding to neddylated cullins (90–95 kDa), whereas free
monomeric Nedd8 (8 kDa) was not detected. That there were
no changes in the levels of Cullin-1, neddylated Cullin-1, or total
Nedd8 conjugates in S-P467L aorta suggests the defect is
specific to Cullin-3 (Figures 4A and 4B). Cullin-3 mRNA was
not different between NT and S-P467L aorta (Figure 4B). The
identity of the neddylated forms of cullins was confirmed by
using the Nedd8-activating enzyme inhibitor MLN4924.
Although there are no Cullin-specific (Cul1, 2, 3, 4A, 4B, 5, 7, 9)
inhibitors, MLN4924 treatment effectively decreases the levels
of neddylated cullins in human and mouse tissues (Soucy
et al., 2009). Treatment of primary rat aortic smooth muscle cells
with MLN4924 eliminated the presence of neddylated Cullin-3,
neddylated Cullin-1, and total Nedd8 conjugates (Figures 4C
and 4D). MLN4924 treatment also increased levels of RhoA,
a Cullin-3 substrate (Figures 4C and 4D).
Cullin-3 Mediates RhoA Turnover in Smooth Muscle
To determine if the decrease in Cullin-3 is mechanistically related
to the increase in RhoA protein in S-P467L aorta, we performed
siRNA-mediated knockdown of Cullin-3 in primary rat aortic
smooth muscle cells. There was no effect of negative control
NC1 siRNA whereas two different siRNAs directed againstMetabolism 16, 462–472, October 3, 2012 ª2012 Elsevier Inc. 465
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Figure 4. Interference with PPARg Causes
Decreased Cullin-3 and Nedd8-Cullin-3
(A and B) Protein levels of Cullin-3 and neddylated
Cullin-3, Cullin-1 and neddylated Cullin-1, and
total Nedd8 conjugates (Nedd8) in medial aortic
tissue from S-P467L and NT mice determined by
western blot (n = 8–9) and their quantification.
Neddylation is the covalent attachment of Nedd8
onto a target protein. The lower molecular weight
band of the doublet (85 kDa) is unneddylated
Cullin-3 or Cullin-1 (denoted as Cul3 or Cul1)
whereas the higher band (95 kDa) is the neddy-
lated Cullin-3 or Cullin-1 product (denoted as
Nedd8-Cul3 or Nedd8-Cul1). Cullin-3 mRNA
expression determined by qPCR (n = 10). See also
Table S1. *p < 0.05 S-P467L versus NT. Error bars
represent SEM.
(C and D) Primary rat aortic smooth muscle cells
treated with the Nedd8-activating enzyme inhib-
itor MLN4924 (1 mmol/L) or DMSO over a time
course of 24 hr. Protein lysates were assessed for
Cullin-3, Cullin-1, Nedd8, and RhoA by western
blot and quantified (n = 4). U, untreated; V, vehicle
(DMSO, 24 hr). ‘‘NS’’ indicates nonspecific band.
*p < 0.05 MLN4924 treated versus vehicle treated.
Error bars represent SEM.
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PPARg Regulates Vascular Function via Cullin-3Cullin-3 decreased its expression by nearly 85% (Figure 5A).
Loss of Cullin-3 expression caused a robust increase in RhoA
and interestingly also increased levels of RhoBTB1 (Figure 5B).
This suggests that RhoBTB1 is a substrate of Cullin-3-mediated
degradation and explains why the level of RhoBTB1 protein was
only modestly decreased in S-P467L aorta. Cyclin E, another
substrate of Cullin-3-mediated degradation (Kossatz et al.,
2010), was also increased by siRNA-mediated Cullin-3 knock-
down in cells (Figure 5B) and in S-P467L aorta (data not shown).
siRNA-mediated knockdown of RhoBTB1 in primary rat aortic
smooth muscle cells caused a modest yet significant decrease
in Cullin-3 and neddylated Cullin-3 protein and a trend toward
increased RhoA, but this was not as dramatic as Cullin-3 knock-
down (Figure S4B). Interestingly, analysis of both oligonucleotide
and exonmicroarrays revealed no changes in the level of mRNA-
encoding proteins involved in neddylation and BTB-domain
containing proteins other than RhoBTB1 (Table S1).
Cullin-RING Ligase Activity Regulates Vascular Function
and Blood Pressure
We next tested the hypothesis that inhibition of cullin-RING
ligase activity leads to enhanced contraction. We established
above that RhoA protein levels were robustly upregulated by
16 hr after treatment with MLN4924 (Figures 4C and 4D). There-
fore, aortic rings from NT mice were first incubated for 16 hr466 Cell Metabolism 16, 462–472, October 3, 2012 ª2012 Elsevier Inc.ex vivo with MLN4924 or vehicle and
then isometric tension studies were per-
formed in the presence of the inhibitor.
MLN4924 enhanced agonist-induced
contraction to ET-1, 5-HT, and PE in NT
aorta, despite blunting receptor-indepen-
dent contraction to KCl (Figures 6A–6D).
Preincubation with the Rho-kinase inhib-itor Y-27632 was effective at blocking the MLN4924-dependent
enhanced contractile responses (Figures 6A–6D). Acute treat-
ment of the vessels with MLN4924 for only 1 hr was not sufficient
to alter reactivity, whereas long-term treatment of aortic rings
from NT mice ex vivo with MLN4924 for 6 days produced the
same results as 16 hr (data not shown). We next tested if the
enhanced agonist-induced contraction in S-P467L mice was
occurring through this mechanism. Consistent with a loss of
Cullin-3 mediated activity, the effect of MLN4924 was markedly
blunted in S-P467L aorta (Figures 6E–6H). Together these data
show that inhibition of cullin-RING ligase activity causes striking
alterations in vascular contractility, likely in part through loss of
Cullin-3-mediated regulation of RhoA/Rho-kinase signaling.
Finally, to provide an in vivo correlate to the vascular function
experiments, we measured arterial pressure by radiotelemetry in
conscious NT and S-P467L mice in response to MLN4924 using
a previously established dose regimen (Soucy et al., 2009; Smith
et al., 2012). Compared to baseline, continuous administration of
MLN4924 (subcutaneous injections; 30 mg/kg TID, 2.5 days)
caused a significant increase in daytime arterial pressure in
normal NT mice (Figures 7A and S5). Baseline arterial pressure
was significantly higher in S-P467L mice, but MLN4924 treat-
ment did not raise arterial pressure further. MLN4924 treatment
caused a marked decrease in spontaneous activity during the
nighttime hours (Figure 7B) that was equivalent in both NT and
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PPARg Regulates Vascular Function via Cullin-3S-P467L mice. The decrease in activity correlated to a loss of
normal diurnal variation in arterial pressure and heart rate that
was also independent of genotype (Figures 7A–7C). MLN4924
administration significantly reduced the level of neddylated
Cullin-3 and total Nedd8-conjugates and increased RhoA
protein in aortic tissue from NT mice (Figure 7D). These data
suggest that cullin-RING ligase activity may be important for
blood-pressure regulation and are consistent with the hypoth-
esis that loss of Cullin-3 in the vasculature contributes to hyper-
tension. Indeed, mutations in Cullin-3 cause severe early-onset
hypertension (Boyden et al., 2012), although the tissue-specific
actions of Cullin-3 remain unclear. The hypertension in patients
harboring Cullin-3 mutations was associated with changes in
ion homeostasis, namely potassium and bicarbonate balance
(Boyden et al., 2012). Blood electrolytes, except for decreased
blood urea nitrogen (BUN), were normal in untreated S-P467L
mice compared to NTmice (Table S2). SystemicMLN4924 treat-
ment caused mild hyperkalemia, decreased hematocrit, and
increased BUN that was also not specific to genotype (Table S2).
DISCUSSION
PPARg within the vascular wall has a pivotal role in protecting
against vascular dysfunction or abnormal vascular growth and
remodeling during hypertension (Diep et al., 2002); however,
the mechanisms behind such improvements remain unclear.
PPAR/RXR heterodimers, bound to corepressors, actively
silence transcription at PPAR response elements (PPREs).
Ligand activation stimulates coactivators to replace corepres-
sors and allow transcription of target genes (Gronemeyer et al.,
2004). Interestingly, genetic deletion of PPARg causes induction
of some genes due to loss of PPAR-dependent active repres-Cellsion, which may mimic PPARg activation (Chang et al., 2009;
Sigmund, 2010). Our approach was guided by the identification
of bona fide mutations in the PPARg ligand-binding domain from
patients who developed early-onset hypertension and insulin
resistance (Barroso et al., 1999; Savage et al., 2003). Mice
homozygous for the equivalent PPARg P465L knockin mutation
die in utero, confirming that the DN mutation is detrimental to
receptor function (Tsai et al., 2004). PPARg P465L heterozygous
(P465L/+) mice develop hypertension and features of metabolic
syndrome (Tsai et al., 2004). Global gene-expression analysis
validated that PPARg target genes induced by agonist treatment
were also repressed by DN PPARg in vascular tissue (Keen et al.,
2010; Keen et al., 2004). Herein, we combined physiological,
biochemical, and bioinformatic approaches to identify PPARg
target genes that regulate vascular function and arterial
pressure.
Themechanisms contributing to vascular dysfunction induced
by smooth muscle-specific expression of DN PPARg are as
follows: (1) endothelium-dependent production of NO is pre-
served; (2) enhanced Rho-kinase activity is responsible for
increased agonist-induced contraction, impaired NO-mediated
relaxation, and increased arterial pressure in S-P467L mice; (3)
increased RhoA protein and RhoA-GTP upstream of Rho-kinase
results from impaired Cullin-3-mediated RhoA turnover in
vascular muscle; (4) RhoBTB1, which interacts with Cullin-3, is
a PPARg target gene and is downregulated by DN PPARg in
vascular muscle; (5) pharmacological inhibition of cullin-RING
ligase activity in aortic segments from wild-type mice causes
augmented agonist-induced contraction that is Rho-kinase
dependent; and (6) inhibition of cullin-RING ligase activity in
wild-type mice in vivo causes increased daytime arterial
pressure.Metabolism 16, 462–472, October 3, 2012 ª2012 Elsevier Inc. 467
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Figure 6. Inhibition of Total Cullin Activity Enhances Agonist-Medi-
ated Contraction
(A–H) Isometric tension data on aortic rings from NT mice (A–D; n = 10) or
S-P467Lmice (E–H; n = 6) incubated in DMEM/F12 (37C, 5%CO2) with DMSO
or MLN4924 (1 mmol/L) for 16 hr. DMSO and MLN4924 were continuously
applied throughout the tension experiments. Contractile responses were re-
corded to ET-1 (A and E), 5-HT (B and F), phenylephrine (PE) (C and G), or KCl
(D and H). Aortic rings from NT mice (A–D) were further studied in the absence
or presence of Rho-kinase inhibitor (30 min preincubation; Y-27632, 1 mmol/L)
(n = 6). Data are normalized to maximum contraction (fold of 100 mmol/L KCl).
*p < 0.05 MLN4924 treated versus vehicle treated. # p < 0.05 Y-27632 treated
versus MLN4924- or vehicle treated alone. Error bars represent SEM.
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PPARg Regulates Vascular Function via Cullin-3Increased RhoA/Rho-kinase activity is implicated in the path-
ogenesis of many cardiovascular diseases, although the under-
lying causes are not well understood (Budzyn et al., 2006). Basal
release of NO from the endothelium prevents activation of RhoA/
Rho-kinase in smooth muscle through PKG-dependent inhibi-
tory phosphorylation of RhoA (Sauzeau et al., 2000). Excessive
reactive oxygen species (ROS; e.g., superoxide) inactivate NO,
leading to a reduction of NO bioavailability and increased
vascular tone, at least in part through elevated RhoA/Rho-kinase
activity (Jin et al., 2006). However, our results suggest that
increased activation of Rho-kinase in S-P467L aorta is neither
a result of oxidative stress nor decreased bioavailability of endo-
thelium-derived NO but is most likely due to a primary defect in
the smooth muscle. This is consistent with the genetic lesion
being targeted to the smooth muscle.468 Cell Metabolism 16, 462–472, October 3, 2012 ª2012 Elsevier InWe next sought to determine the primary PPARg-dependent
effect on regulators upstream of Rho-kinase. The dual regulation
of MLC phosphorylation through Ca2+-dependent activation of
MLCK and RhoA/Rho-kinase-dependent inhibition of MLCP is
attributed to the coupling of G protein-coupled receptors
(GPCRs) to Gaq/11 and Ga12/13, respectively (Maguire and
Davenport, 2005; Wirth et al., 2008). Stimulation of aortic smooth
muscle cells with agonists of GPCRs including ET-1, 5-HT, and
PE, in addition to high KCl, enhances RhoA-GTP, which acti-
vates Rho-kinase (Sakurada et al., 2001, 2003; Momotani
et al., 2011). We provide clear evidence of increased RhoA
protein, RhoA-GTP, and Rho-kinase activity in S-P467L aorta.
Thus, PPARg-dependent regulation of the RhoA/Rho-kinase
and NO/PKG-dependent signaling in smooth muscle is key in
shifting the balance between vasoconstrictor and vasodilator
responses. The PPARg agonist pioglitazone was shown to lower
systolic blood pressure and suppress RhoA/Rho-kinase activity
in aortic tissue of spontaneously hypertensive rats (SHR)
(Wakino et al., 2004). Similarly, upregulation of RhoA in Dahl
salt-sensitive hypertensive rats was decreased by telmisartan,
a dual ARB/PPARg agonist (Kobayashi et al., 2008). Whereas
reports have demonstrated that activation of PPARg with TZDs
suppresses RhoA/Rho-kinase signaling in microvascular endo-
thelial cells (Ramirez et al., 2008), monocytes (Toriumi et al.,
2003), and neurons (Dill et al., 2010), the mechanisms are not
established.
Expression of DN PPARg in smooth muscle of S-P467L mice
caused increased RhoA protein level in the aorta; however, this
was not associated with a change in RhoA mRNA, suggesting
a potential alteration in posttranslational regulation of RhoA.
This was supported by gene-expression profiling, revealing
a marked decrease in RhoBTB1, an atypical Rho GTPase that
lacks GTPase activity. RhoBTB1 binds to the N-terminal region
of Cullin-3 through its BTB domain (Berthold et al., 2008).
RhoA is a substrate targeted by the Cullin-3 E3 RING ubiquitin
ligase complex for ubiquitylation and subsequent degradation
in the proteasome (Chen et al., 2009). Silencing of human
Cullin-3 caused a loss of RhoA ubiquitylation and accumulation
of RhoA protein and RhoA-GTP—and induced actin stress fiber
formation that was RhoA-dependent in HeLa cells (Chen et al.,
2009). We found decreased levels of Cullin-3 and neddylated
Cullin-3 in aorta from S-P467L mice. The decreased ratio of
Nedd8-conjugated Cullin-3 to unneddylated Cullin-3 is impor-
tant because the neddylation of cullins is required for cullin-
RING ubiquitin ligase activity (Petroski and Deshaies, 2005).
Our data support that loss of Cullin-3 in primary rat aortic smooth
muscle cells causes accumulation of its substrates, including
RhoA and Cyclin E, and raised the possibility that inhibition of
Cullin-3 activity may regulate vascular reactivity. To test this,
we used MLN4924, an inhibitor of Nedd8-activating enzyme,
which catalyzes Nedd8 conjugation onto cullins (Soucy et al.,
2009). MLN4924 treatment blocked neddylation of Cullin-3 and
Cullin-1 and completely blocked the formation of total Nedd8-
conjugates in primary rat aortic smooth muscle cells. This
suggests a remarkable specificity of Nedd8 conjugation onto
cullins in vascular tissue. Treatment of aorta from wild-type (NT
control) mice with MLN4924 caused increased agonist-induced
contraction that, despite the broad effects of cullin inhibition,
was Rho-kinase dependent. This is consistent with studiesc.
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Figure 7. Inhibition of Total Cullin Activity
Increases Daytime Blood Pressure in
Normal Mice
(A–C) Systolic blood pressure (A), spontaneous
activity (B), and heart rate (C) recorded continu-
ously throughout the light:dark cycle by radiote-
lemetry in NT (n = 9) and S-P467L mice (n = 7).
Baseline measurements were taken for 7 days. At
the beginning of the light phase, mice began
continuous dosing with MLN4924 (subcutaneous
injections; 30 mg/kg TID). Data represent the
average of the baseline measurements (7 days)
and the average of MLN4924 treatment over
2.5 days (60 hr). See also Figure S5 and Table S2.
# p < 0.05 MLN4924 treatment versus baseline.
*p < 0.05 S-P467L versus NT. a p < 0.05 dark cycle
versus light cycle. Error bars represent SEM.
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PPARg Regulates Vascular Function via Cullin-3reporting thatMLN4924 treatment of HEK293 cells caused accu-
mulation of RhoA protein and altered cell morphology that was
completely reversed by siRNA-knockdown of RhoA (Leck
et al., 2010). Our in vivo studies revealed that systemic adminis-
tration of NTmice withMLN4924 caused a significant increase in
arterial pressure, at least during the light phase, whereas its
administration to S-P467L mice did not. This supports our
conclusion that the impairment of Cullin-3-mediated regulation
of RhoA in the vasculature contributes to hypertension. Systemic
MLN4924 treatment also had nonspecific effects on the normal
diurnal variation in arterial pressure, heart rate, and activity.
Consequently, use of gene-targeted mice would better clarify
the actions of specific cullins in the blood vessel.
Cullin-based E3 ubiquitin ligases are dimeric, and Cullin-3/
substrate homooligomers are dependent on substrate dimer
formation (Chew et al., 2007). Cullin-3 is the only cullin-RING
ligase member reported to bind to BTB domain-containing
proteins for its substrate specificity (Petroski and Deshaies,
2005). The finding that RhoBTB1 is a PPARg target gene down-Cell Metabolism 16, 462–472regulated by DN PPARg in S-P467L aorta
was instrumental in discovering the
accompanying decrease in Cullin-3, and
suggests that RhoBTB1 may regulate
Cullin-3 level or activity. It has been
hypothesized that RhoBTBs may regu-
late the targeting of specific Cullin-3
substrates, including RhoA. This is based
on the observation that RhoBTB1 and
RhoBTB2 are candidate tumor suppres-
sors, and their loss correlates with
increased RhoA protein in breast and
head and neck cancers (Beder et al.,
2006; Nethe and Hordijk, 2010). Our
results from siRNA knockdown of
RhoBTB1 suggest that its down-
regulation partially explains decreased
Cullin-3 levels, indicating perhaps some
other PPARg-dependent or PPARg-inde-
pendent effects are involved in this
mechanism. Some candidates are BTB
domain-containing RhoA-binding pro-teins (BACURDs), which were recently identified to be adaptors
for Cullin-3 mediated RhoA ubiquitylation (Chen et al., 2009).
Expression of BACURDs, at least at the mRNA level, did not
appear to be regulated by PPARg in vascular muscle on the
basis of our microarray data (Table S1). Identifying which
adaptor proteins control substrate specificity for Cullin-3
remains under active investigation, and new substrates for
Cullin-3:RhoBTB-domain-mediated ubiquitylation continue to
be uncovered (Schenkova et al., 2012). Additional investigation
will be required to determine the full range of substrates the
RhoBTB family of proteins anchor to Cullin-3.
A role for Cullin-3 in hypertension has recently been reported
(Boyden et al., 2012). Remarkably, greater than 90% of patients
with dominant mutations in cullin-3 developed hypertension
before the age of 18, as did about 15%of patients withmutations
in KLHL3, a Cullin-3 substrate adaptor. The mutations were
discovered from a group of patients with pseudohypoaldoster-
onism type II (PHAII), a syndrome characterized by hypertension,
hyperkalemia, and metabolic acidosis. Our data indicate that, October 3, 2012 ª2012 Elsevier Inc. 469
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PPARg Regulates Vascular Function via Cullin-3hypertension caused by smooth muscle-specific expression
of DN PPARg in S-P467L transgenic mice is not related to
changes in electrolyte balance. Patients with DN mutations in
PPARg also develop early-onset hypertension but have nor-
mal serum potassium levels (Savage et al., 2003). In PHAII,
cullin-3 mutations may not only perturb renal ion transport as
demonstrated for mutations in one of its partners KLHL3
(Louis-Dit-Picard et al., 2012), but perhaps may also provoke
a severe and early-onset hypertension (Boyden et al., 2012) by
increasing vascular contraction and impairing the response to
NO. Together these findings lead to the hypothesis that hyper-
tension caused by cullin-3 mutations may be due in part to
impaired Cullin-3-mediated regulation of RhoA/Rho-kinase in
vascular smooth muscle. We conclude that interference with
PPARg signaling, either through mutation or perhaps through
inhibitory modification (i.e., Cdk5-mediated phosphorylation at
Serine 273) (Choi et al., 2011), causes a decrease in Cullin-3
activity associated with loss of the Cullin-3-interacting protein
RhoBTB1. Impaired Cullin-3-dependent degradation of RhoA
results in enhanced RhoA/Rho-kinase signaling and causes
an imbalance in responsiveness to vasodilator and vaso-
constrictor signals leading to hypertension. Hence, under
normal conditions PPARg facilitates tight regulation of RhoA/
Rho-kinase activity via Cullin-3-mediated turnover of RhoA.
Future studies are needed to discern the extent that aberrant
regulation of Cullin-3 activity or expression in the vasculature
and other tissues contributes to hypertension and cardiovas-
cular disease.EXPERIMENTAL PROCEDURES
Transgenic Mouse Model
S-P467L transgenic mice were described previously and were backcross bred
to C57BL/6J for at least ten generations (Halabi et al., 2008). All mice were fed
standard mouse chow (7013, Teklad Premier Laboratory Diets) and water ad
libitum. Care of the mice used in the experiments met the standards set forth
by the National Institutes of Health (NIH) guidelines for the care and use of
experimental animals. All procedures were approved by the University of
Iowa Institutional Animal Care and Use Committee.
Wire Myograph Preparation
Isometric tension was measured on aorta from mice 5–6 months of age as
reported (Halabi et al., 2008; Beyer et al., 2008). Mice were given a lethal
dose of pentobarbital (50 mg/mouse IP). Thoracic aorta was removed and
placed in oxygenated Krebs buffer, dissected free of adventitial fat, and cut
into 4 segments 4–5 mm in length. Where necessary the endothelial cell layer
was removed by rubbing the lumen with a trimmed wooden toothpick. Aortic
rings were suspended in organ baths containing 20 ml Krebs buffer (main-
tained at 37C and 95% O2/5% CO2) and connected to a force transducer
to measure isometric tension; resting tension was set to 0.5 g, and the
aortic rings were equilibrated for 45 min. Contraction was recorded for ET-1
(0.1–100 nmol/L), 5-HT (0.01–30 mmol/L), PE (0.01–30 mmol/L), PGF2a
(0.1–30 mmol/L), and KCl (10–100 mmol/L). Relaxation was recorded for
Ach (0.01–30 mmol/L), SNP (1–10,000 nmol/L) after initial submaximal precon-
traction (40%–50% of max) with PGF2a. In some experiments, two aortic rings
were preincubated (30 min) with the drug, while two other segments were
untreated. These include 100 mmol/L L-NAME, 1 mmol/L Y-27632, and
10 mmol/L Tempol. For studies on Ca2+ sensitivity, aortic rings were equili-
brated, then switched to Ca2+-free Krebs buffer with three washes over a
period of 15 min. Vessels were then treated with 3 mmol/L ionomycin (in
DMSO) for 30 min. Contractile responses were recorded for CaCl2
(0.01 mmol/L-100 mmol/L in Ca2+-free Krebs). For experiments using
MLN4924, aortic rings were incubated in DMEM/F12 (16 hr or 6 day; 37C,470 Cell Metabolism 16, 462–472, October 3, 2012 ª2012 Elsevier In5%CO2) with either DMSO or 1 mmol/L MLN4924 (in DMSO) prior to prepara-
tion onto wire myograph. DMSO or 1 mmol/L MLN4924 was continuously
applied to organ baths after each wash during equilibration and throughout
the length of the tension studies. Data were collected with PowerLab/8SP
and analyzed with Chart 5 software (AD Instruments).
Blood Pressure Analysis
First, S-P467L and NT mice 5–6 months of age were anesthetized with pento-
barbital (60 mg/kg intraperitoneally), and cannulation of the carotid artery and
jugular vein with 0.040 O.D. sterile tubing was performed. Acute blood-
pressure responses were measured during anesthesia. Depressor effects
were measured in response to Y-27632 (0.1–10 mg/kg through the venous
catheter). Data were collected with PowerLab/8SP and analyzed with Chart
5 software (AD Instruments). Second, blood pressure was measured by radio-
telemetry as described (Beyer et al., 2008; Halabi et al., 2008). After 7 days of
recovery, arterial pressure, heart rate, and activity were continuously recorded
(sampling every 5 min for 20 s intervals). Baseline blood pressure was
measured for 7 days. At the beginning of the light phase, mice began contin-
uous treatment with MLN4924 (in 10% hydroxy-propyl-b-cyclodextrin) by
subcutaneous injections (30 mg/kg TID), and blood pressure was recorded
and analyzed over the next 60 hr (2.5 days). Data were collected and stored
using Dataquest ART. Mice were sacrificed at 1 hr following the final injection
at 72 hr (3 days). Cheek puncture blood samples were collected and analyzed
using i-STAT system CG4+ and CHEM8+ cartridges. Aortic tissue was
harvested for protein analyses.
Cell Culture, siRNA Gene Silencing, and Western Blotting
Primary smooth muscle cells were isolated from thoracic aorta of S-P467L or
NT mice. They were dissected free of perivascular fat; cut into small pieces;
and dissociated with collagenase, elastase, soybean trypsin inhibitor, and
bovine serum albumin type I at 37C for 30 min. The suspension was centri-
fuged at 2000 rpm for 5min, the pellet was resuspended, and cells were plated
and maintained in DMEM with 10% FBS, 100 U/ml penicillin, and 100 mg/ml
streptomycin at 37C and 5% CO2. The medium was replaced every 48 hr.
Once confluent, the cells were passaged and verified as smooth muscle by
staining with a-actin and calponin. Subconfluent smooth muscle cells at
passages 2–4 were used for experiments. Primary culture of aortic smooth
muscle cells from Sprague Dawley rat was a gift from Amy Banes-Berceli
(Oakland University, MI). Rat aortic smooth muscle cells were maintained in
low glucose (1 g/L) DMEM with 10% FBS, 100 U/ml penicillin, and
100 mg/ml streptomycin and kept at 37C and 5% CO2. Cells were cultured
1 day prior to transfection with 20 nmol/L negative control NC1 siRNA or siRNA
duplexes targeted to rat Cullin-3 or RhoBTB1 (Integrated DNA Technologies;
Coralville, IA) using Hiperfect (QIAGEN) using the manufacturer’s protocol.
Cells were harvested 72 hr later and total protein lysates were stored
at 80C. Rat aortic smooth muscle cells were treated with MLN4924
(1 mmol/L) for 2, 4, 8, 16, and 24 hr or vehicle control (DMSO) for 24 hr and har-
vested for total protein lysates. Experimental procedures for tissue prepara-
tion, transfections, immunoprecipitation, western blotting, and the antibodies
used are described in detail in the Supplemental Experimental Procedures.
Rho-Kinase and Rho GTPase Pull-Down Assay
Rho-kinase-dependent phosphorylation of its substrate MYPT1 was
measured in aorta and primary aortic smooth muscle cells by ELISA, and
Rho GTPase activity was determined by pull-down for the active GTP-bound
forms of RhoA, Rac1, or Cdc42. The assays are described in detail in the
Supplemental Experimental Procedures.
Real-Time RT-PCR, Microarray Analysis, and Chromatin
Immunoprecipitation
Real-time PCR (qPCR) analysis was performed using TaqMan Gene Expres-
sion Assays. Two independent microarray experiments (series accession:
GSE37196) were performed using different array platforms: the Affymetrix
mouse genome 2.0 array and the Affymetrix mouse exon 1.0 ST array. Chro-
matin immunoprecipitation was performed on differentiated 3T3-L1 cells.
The experimental procedures for these analyses are described in detail in
the Supplemental Experimental Procedures.c.
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Ach, SNP, KCl, 5-HT, PE, and Nu-Nitro-L-arginine methyl ester (L-NAME)
were obtained from Sigma; PGF2a from Pfizer; and Y-27632 from Calbiochem;
all of these reagents were dissolved in saline. ET-1 was obtained from
Peninsula Laboratories Inc., and dissolved in water. MLN4924 (Active-
Biochem), ionomycin (Calbiochem), Bay K8644 (Sigma), and Phorbol 12,13-
dibutryate (Sigma) were dissolved in DMSO.
Statistical Analyses
All data are expressed as mean ± SEM. Data were analyzed with 1- or 2-way
analysis of variance (ANOVA, repeated measures when appropriate) using
Tukey or Bonferroni post hoc tests. Data sets failing normality or equal
variance assumptions, or with small n (n < 5), were analyzed using nonpara-
metric comparisons (Friedman’s ANOVA or Mann-Whitney U Test). p < 0.05
was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.08.011.
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